Status:
UNKNOWN
Characterizing IgG4-RD With 68Ga-FAPI PET/CT
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
IgG4-related Disease
Eligibility:
All Genders
18-90 years
Phase:
EARLY_PHASE1
Brief Summary
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as IgG4-related disease.And it mig...
Detailed Description
Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory condition that is capable of affecting multiple organs. Common forms of presentation include:Type 1 (IgG4-related) a...
Eligibility Criteria
Inclusion
- suspected or confirmed untreated IgG4-RD patients;
- 18F-FDG PET/CT within two weeks;
- signed written consent.
Exclusion
- pregnancy;
- breastfeeding;
- known allergy against FAPI
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04125511
Start Date
November 1 2019
End Date
December 1 2021
Last Update
January 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730